Insulin glargine/lixisenatide in type 2 diabetes: a profile of its use
- 82 Downloads
Subcutaneous insulin glargine/lixisenatide [Suliqua® 100/33 and 100/50 (EU); Soliqua® 100/33 (USA)] is a titratable, fixed-ratio combination of a long-acting basal insulin analogue + a glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved to treat inadequately controlled type 2 diabetes (T2D) in adults. Once-daily insulin glargine/lixisenatide provided glycaemic control better than that of insulin glargine or lixisenatide in insulin-naive patients (when added to metformin) and better than that of insulin glargine in insulin-experienced patients (when used ± metformin) in phase 3 trials in adults with inadequately controlled T2D. It also had a beneficial effect on bodyweight and did not increase the frequency of hypoglycaemia versus insulin glargine. Insulin glargine/lixisenatide is generally well tolerated and offers the convenience of once-daily administration of two subcutaneous antihyperglycaemic agents. It is, therefore, a valuable option for improving glycaemic control in adults with T2D when this has not been provided by metformin alone or metformin + another oral antihyperglycaemic agent or + basal insulin.
The manuscript was updated from Drugs 2017;17(12):1353–62 , and was reviewed by: S.C. Bain, Swansea University Medical School, Swansea, UK; G. Dimitriadis, 2nd Department of Internal Medicine, Research Institute and Diabetes Center, Athens University Medical School, Attikon University Hospital, Haidari, Greece; T. Tzotzas, St Luke’s General Hospital, Thessaloniki, Greece. During the peer review process, Sanofi-Aventis, the marketing-authorization holder of insulin glargine/lixisenatide, was also offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with ethical standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
Emma Deeks is an employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no conflicts of interest.
- 2.Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centered approach. Update to position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–9.CrossRefGoogle Scholar
- 12.Suliqua (insulin glargine 100 units/mL + lixisenatide 33 or 50 micrograms/mL) solution in a prefilled pen: summary of product characteristics. Paris: Sanofi-Aventis Groupe; 2019.Google Scholar
- 13.Soliqua 100/33 (insulin glargine and lixisenatide injection), for subcutaneous use: US prescribing information. Bridgewater (NJ): sanofi-aventis US LLC; 2019.Google Scholar
- 17.Meier JJ, Menge B, Schenker N, et al. Mechanisms of action of the glucose-lowering effect of lixisenatide in combination with insulin glargine [abstract no. 281-OR]. Diabetes. 2015;64(Suppl 1):A74.Google Scholar
- 18.Kovatchev B, Umpierrez G, Renard E. The differential and combined action of insulin glargine and lixisenatide on the fasting and post-prandial components of glucose control [abstract no. 3]. Diabetologia. 2016;59(Suppl 1):S2.Google Scholar
- 22.Rosenstock J, Aronson R, Grunberger G, et al. Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial. Diabetes Care. 2016;39(11):2026–35.CrossRefGoogle Scholar
- 23.Aroda VR, Rosenstock J, Wysham C, et al. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial. Diabetes Care. 2016;39(11):1972–80.CrossRefGoogle Scholar
- 24.Ritzel R, Vidal J, Aroda VR, et al. Efficacy and safety across the final dose ranges in patients with T2DM receiving insulin glargine/lixisenatide fixed-ratio combination in the LixiLan-L trial [abstract no. 1024-P]. Diabetes. 2016;65(Suppl 1):A266–7.Google Scholar
- 25.Davis M, Leiter LA, Grunberger G, et al. Impact of baseline HbA1c, BMI, and diabetes duration on the efficacy and safety of LixiLan (insulin glargine/lixisenatide titratable fixed-ratio combination) vs. insulin glargine and lixisenatide in the LixiLan-O trial [abstract no. 1028-P]. Diabetes. 2016;65(Suppl 1):A268.Google Scholar
- 26.Wysham C, Bonadonna RC, Aroda VR, et al. Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. Diabetes Obes Metab. 2017;19(10):1408–15.CrossRefGoogle Scholar
- 27.Handelsman Y, Chovanes C, Dex T, et al. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination in elderly patients with T2D [abstract no. 954-P]. Diabetes. 2016;65(Suppl 1):A246.Google Scholar
- 29.Desouza C, Fonseca V, Frias JP, et al. Glycemic target attainment in insulin-naive patients with T2D receiving iglarlixi [abstract no. 1093-P]. Diabetes. 2018;67(Suppl 1):A291.Google Scholar
- 30.Giorgino F, Retnakaran R, Vidal J, et al. iGlarlixi effectively reduces residual hyperglycemia in patients with type 2 diabetes on basal insulin-a post-hoc analysis from the LixiLan-l study [abstract no. 1095-P]. Diabetes. 2018;67(Suppl 1):A292.Google Scholar
- 31.Mora P, Chao J, Saremi A, et al. Relationship of ethnicity to clinical outcomes in iglarlixi-treated patients with type 2 diabetes [abstract no. 1072-P]. Diabetes. 2018;67(Suppl 1):A284.Google Scholar
- 32.Dailey G, Bajaj HS, Dex T, et al. Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed-ratio combination in North American patients compared with the rest of world. BMJ Open Diabetes Res Care. 2019;7(1).Google Scholar
- 34.Aronson R, Umpierrez G, Stager W, et al. Insulin glargine/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia. Diabetes Obes Metab. 2019;21(3):726–31.Google Scholar
- 37.Davies MJ, Russell-Jones D, Barber TM, et al. Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial. Diabetes Obes Metab. 2019;21(8):1967–72.CrossRefGoogle Scholar
- 38.Blonde L, Berard L, Saremi A, et al. Impact of type 2 diabetes (T2D) duration on response to iglarlixi vs. Iglar:a subanalysis of LixiLan-L [abstract no. 1094-P]. Diabetes. 2018;67(Suppl 1):A291–2.Google Scholar
- 39.Leiter LA, Chao J, Saremi A, et al. A1c target attainment in patients with T2D receiving iGlarLixi who reach PPG and FPG targets in the Lixilan-L trial [abstract no. 1089-P]. Diabetes. 2018;67(Suppl 1):A290.Google Scholar
- 45.Zannad F, Stough WG, Lipicky RJ, et al. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. Eur Heart J. 2016;2:200–5.Google Scholar
- 46.Committee for Medicinal Products for Human Use (CHMP). Guidelines on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus: revision 1. London: European Medicines Agency; 2012.Google Scholar
- 50.Montagnoli R, Lastoria G, Parekh W, et al. Long-term cost-effectiveness analysis of IDegLira versus iGlarLixi for the treatment of patients with poorly controlled type 2 diabetes on basal insulin in the Italian setting [abstract no. PDB77]. Value Health. 2018;21(Suppl 3):S131.Google Scholar
- 51.Hvid C, Parekh W, Pohlmann J, et al. Cost-effectiveness of treating patients with type 2 diabetes poorly controlled on basal insulin with fixed-ratio combinations of basal insulin and Glp-1 receptor agonists in Denmark: IDegLira versus iGlarLixi [abstract no. PDB75 + poster]. Value Health. 2018;21(Suppl 3):S131.Google Scholar
- 53.Stryker MD, Blow CA, Friedman EB, et al. Assessing the real-world use of combination insulin glargine-lixisenatide in patients with type 2 diabetes mellitus:a retrospective review from an ambulatory care endocrinology practice [abstract no. 2290-PUB]. Diabetes. 2018;67(Suppl 1):A598.Google Scholar
- 56.Rosenstock J, Handelsman Y, Vidal J, et al. Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. Diabetes Obes Metab. 2018;20(12):2821–9.CrossRefGoogle Scholar